期刊文献+

分泌IL-21的白血病细胞系的建立及其抑瘤作用 被引量:1

Establishment of leukemia cell lines expressing IL-21 and analysis of anti-tumor function
下载PDF
导出
摘要 目的建立及鉴定稳定表达白介素21的4种白血病细胞系,并初步分析其刺激活化的淋巴细胞对肿瘤细胞的杀伤功能。方法构建携带白介素21和红色荧光蛋白基因的质粒,包装慢病毒,感染4种白血病细胞系,连续传代后,通过荧光显微镜、流式细胞仪和ELISA法鉴定建立的4种细胞系。以稳定分泌IL-21白血病细胞为抗原刺激外周血单个核细胞增殖,细胞分析计数仪检测增殖倍数,流式细胞仪分析淋巴细胞的表型,细胞计数试剂盒(CCK8)检测增殖后的淋巴细胞对肿瘤细胞的杀伤作用。结果建立稳定表达IL-21的4种细胞系:K562-IL-21、THP-1-IL-21、jurkat E6-1-IL-21和RPMI8226-IL-21。3份人PBMC在4种分泌IL-21的白血病细胞的作用下都有增殖,增殖倍数在1.147±0.057~2.725±0.345倍之间。不同数量的IL-21分泌白血病细胞都可激活淋巴细胞增殖,增殖的倍数在1.127±0.152~2.213±0.200之间。增殖后CD3+T淋巴细胞和CD56+NK细胞的比例降低(P<0.05),CD19+B淋巴细胞比例增加(P<0.05);由分泌IL-21白血病细胞激活后的淋巴细胞对母系白血病细胞的杀伤作用明显高于对照组。由分泌IL-21白血病细胞激活后的淋巴细胞对母系白血病细胞和其他7种肿瘤细胞均有杀伤作用,杀伤率在(28.68±9.31)%^(78.45±0.61)%之间。结论 4种分泌IL-21的白血病细胞可刺激PBMC增殖并激活其对肿瘤细胞的杀伤作用。 Objective To establish leukemia cell lines expressing IL-21 constitutively,and to analyze the activation function on lymphocytes by those cell lines.Methods Four leukemia cell lines were infected with lentivirus carrying IL-21 and RFP genes.Fluorescent microscope was used for observing the expression of RFP and flow cytometry was used for analyzing the percentage of RFP-positive cells.The concentration of IL-21 in the medium was detected by ELISA.After stimulation with the IL-21 stable-expressing leukemia cell lines,the amplification of PBMC were calculated by cell counter and the surface markers were analyzed by flow cytometry,while their cytotocicity towards different tumor cells were assessed with CCK8 test.Results Four leukemia cell lines stable-expressing IL-21 were established,namely,K562-IL-21,THP-1-IL-21,jurkat E6-1-IL-21 and RPMI8226-IL-21.The lymphocytes amplification of 3 different samples varied from 1.147 ±0.057 to 2.725 ±0.345 times and the amplification folds of lymphocytes stimulated by different numbers of leukemia cells varied from 1.127 ±0.152 to 2.213 ±0.200.The percentage of CD3 + T cell and CD56 + NK cell decreased (P 〈 0.05) while CD19 + B cells increased (P 〈 0.05) after stimulation.The killing rate of activated lymphocytes is much higher than that of control.The activated lymphocytes had powerful killing capacity on their stimulating leukemia cells and 7 other tumor cells and the killing rates ranged from 28.68 ± 9.31% to 78.45 ± 0.61%.Conclusions Four leukemia cell lines stable-expressing IL-21 may activate PBMC to kill different tumor cells.
出处 《基础医学与临床》 CSCD 北大核心 2014年第7期961-967,共7页 Basic and Clinical Medicine
关键词 白血病细胞系 白介素21 肿瘤治疗 leukemia cell lines interleukin-21 tumor therapy
  • 相关文献

参考文献1

二级参考文献13

  • 1Parrish-Novak J,Dillon SR,Nelson A. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function[J].Nature,2000.57-63.
  • 2Monteleone G,Pallone F,Macdonald TT. Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease[J].Cytokine & Growth Factor Reviews,2009.185-191.
  • 3Zhao MF,Deng Q,Li YM. Interleukin 21 enhances the expansion and anti-tumor cytotoxic activity of cytokine-induced killer cells derived from both peripheral blood and cord blood in vitro[C/OL]//ASH annual meeting[J].Blood,2007.4887.
  • 4Hashmi MH,Van Veldhuizen PJ. Interleukin-21:updated review of Phase Ⅰ and Ⅱ clinical trials in metastatic renal cell carcinoma,metastatic melanoma and relapsed/refractory indolent nonHodgkin's lymphoma[J].Expert Opinion on Biological Therapy,2010.807-817.
  • 5Andorsky DJ,Timmerman JM. Interleukin21:biology and application to cancer therapy[J].Expert Opinion on Biological Therapy,2008.1295-1301.
  • 6Davis ID,Brady B,Kefford RF. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage Ⅳ malignant melanoma without prior treatment:a phase Ⅱ a trial[J].Clinical Cancer Research,2009.2123-2129.
  • 7Meazza R,Azzarone B,Orengo AM. Role of commongamma chain cytokines in NK cell development and function:perspectives for immunotherapy[J].Journal of Biomedicine and Biotechnology,2011.861920.
  • 8Coquet JM,Kyparissoudis K,Pellicci DG. IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production[J].Journal of Immunology,2007.2827-2834.
  • 9Vemeris MR,Komacker M,Mail(a)nder V. Resistance of ex vivo expanded CD3 + CD56 + T cells to Fas-mediated apoptosis[J].Cancer Immunology Immunotherapy,2000.335-345.
  • 10Takaki R,Hayakawa Y,Nelson A. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism[J].Journal of Immunology,2005.2167-2173.

共引文献7

同被引文献10

  • 1Thompson JA, Curti BD, Redman BG, et al.Phase Ⅰstudy of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma[J].J Clin Oncol, 2008, 26 ( 12 ) : 2034-2039.
  • 2Fina D, Fantini MC, Pallone F, et al.Role of interleukin- 21 in inflammation and allergy[J].Inflamm Allergy Drug Targets, 2007,6 ( 1 ) : 63-68.
  • 3Monteleone G, Pallone F, MacDonald TT.Interleukin- 21 : a critical regulator of the balance between effecter and regulatory T-cell responses[J].Trends Iinmunol, 2008,29 ( 6 ) : 290-294.
  • 4Gowda A, Roda J, Hussain SR, et al.IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro[J].Blood, 2008,11 ( 9 ) : 4723-4730.
  • 5Gelebart P, Zak Z, Anand M, et al.Interleukin-21 effectively induces apoptosis in mantle cell lymphoma through a STAT-1 dependent mechanism[J].Leukemia, 2009.23 ( 10)_, 1836-1846.
  • 6Ma J, Ma D, Ji C.The role of IL-21 in hematological malignancies[J].Cytokine,2011,56 ( 2 ) : 133-139.
  • 7赵明峰,翟文静,邓琦,李玉明,耿丽,杨莉,吕海容,林雪梅,刘鹏江,李敬兰.白介素21对树突状细胞诱导的CTL抗白血病作用的影响[J].中国实验血液学杂志,2009,17(3):627-632. 被引量:5
  • 8苏梅芳,王昌锋,赵咏梅,吴继雄,张耀.IL-17和IL-21在急性白血病患者中的表达及意义[J].中国实验血液学杂志,2010,18(5):1143-1146. 被引量:15
  • 9赵楠,赵明峰.白细胞介素21的免疫调节功能及其在血液肿瘤中的作用[J].中国肿瘤临床,2012,29(7):414-417. 被引量:3
  • 10宋建新,朱红艳,沙玲.慢性粒细胞白血病患者血清IL-21水平检测的临床意义[J].国际检验医学杂志,2013,34(16):2103-2104. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部